Evidence map›Paper›PMID 36639681›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Repurposing nitric oxide donating drugs in cancer therapy through immune modulation.

Chung-Yen Li, Gangga Anuraga, Chih-Peng Chang, Tzu-Yang Weng, Hui-Ping Hsu, Hoang Dang Khoa Ta, Pei-Fang Su, Pin-Hsuan Chiu, Shiang-Jie Yang, Feng-Wei Chen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Chung-Yen LiCollege of Medicine, Institute of basic medical sciences, National Cheng Kung University, Tainan, Taiwan, ROC.
Gangga AnuragaPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan, ROC.
Chih-Peng ChangCollege of Medicine, Institute of basic medical sciences, National Cheng Kung University, Tainan, Taiwan, ROC.
Tzu-Yang WengCollege of Medicine, Institute of basic medical sciences, National Cheng Kung University, Tainan, Taiwan, ROC.
Hui-Ping HsuDepartment of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
Hoang Dang Khoa TaPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan, ROC.
Pei-Fang SuDepartment of Statistics, National Cheng Kung University, Tainan, Taiwan, ROC.
Pin-Hsuan ChiuThe Center for Quantitative Sciences, Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
Shiang-Jie YangCollege of Medicine, Institute of basic medical sciences, National Cheng Kung University, Tainan, Taiwan, ROC.
Feng-Wei ChenCollege of Medicine, Institute of basic medical sciences, National Cheng Kung University, Tainan, Taiwan, ROC.
Pei-Hsuan YeDepartment of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
Chih-Yang WangPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan, ROC. chihyang@tmu.edu.tw.
Ming-Derg LaiCollege of Medicine, Institute of basic medical sciences, National Cheng Kung University, Tainan, Taiwan, ROC. a1211207@mail.ncku.edu.tw.
National Cheng Kung University · TWNational Cheng Kung University Hospital · TWTaipei Medical University · TWTaipei Medical University Hospital · TWUniversitas 45 Surabaya · ID

Funding

Ministry of Science and Technology, Taiwan MOST 109-2320-B-038-009Ministry of Science and Technology, Taiwan MOST 110-2320-B-006-039
6 · The paper itself

Abstract

backgroundNitric oxide-releasing drugs are used for cardiovascular diseases; however, their effects on the tumor immune microenvironment are less clear. Therefore, this study explored the impact of nitric oxide donors on tumor progression in immune-competent mice.

methodsThe effects of three different nitric oxide-releasing compounds (SNAP, SNP, and ISMN) on tumor growth were studied in tumor-bearing mouse models. Three mouse tumor models were used: B16F1 melanoma and LL2 lung carcinoma in C57BL/6 mice, CT26 colon cancer in BALB/c mice, and LL2 lung carcinoma in NOD/SCID mice. After nitric oxide treatment, splenic cytokines and lymphocytes were analyzed by cytokine array and flow cytometry, and tumor-infiltrating lymphocytes in the TME were analyzed using flow cytometry and single-cell RNA sequencing.

resultsLow doses of three exogenous nitric oxide donors inhibited tumor growth in two immunocompetent mouse models but not in NOD/SCID immunodeficient mice. Low-dose nitric oxide donors increase the levels of splenic cytokines IFN-γ and TNF-α but decrease the levels of cytokines IL-6 and IL-10, suggesting an alteration in Th2 cells. Nitric oxide donors increased the number of CD8

conclusionsLow concentrations of exogenous nitric oxide donors inhibit tumor growth in vivo by regulating T cells and macrophages. CD8

Indexed as

CarcinomaCD8-Positive T-LymphocytesAnimalsCytokinesDrug RepositioningMiceMice, Inbred C57BLMice, SCIDNitric OxideNitric Oxide DonorsTumor MicroenvironmentCytokinesNitric OxideNitric Oxide DonorsCancerCD8+ cytotoxic T cellsImmuneMacrophagesNitric oxide donorSingle-cell RNA-seqSNAP

Identifiers

PMID36639681
PMCPMC9840268
OpenAlexW4315979051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.